Dr. Reddy's News
Most Popular Dr. Reddy's Story
Dr. Reddy's make risky biogenerics move
At the Motley Fool, Brian Orelli analyzes a recent decision by India-based generic drug developer Dr. Reddy's Laboratories to spend $20 million to produce eight new generic versions of biologics over the next eight years.
... Read more...Latest Headlines
- January 4, 2010
- May 21, 2009
- April 24, 2008
- March 10, 2008
- March 3, 2008
- February 5, 2008
- January 22, 2008
- October 25, 2007
- September 25, 2007
- June 29, 2007
- July 16, 2006
- March 1, 2006
- February 15, 2006
- February 2, 2006
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
